Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLU-945 phase 1/2 study in EGFR-mutant non-small cell lung cancer
jRCT2031210431Phase 2Completed
- Sponsor
- Blueprint Medicines
- Start
- Dec 2021
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of tigozertinib and osimertinib in non-small cell lung cancer (NSCLC) (6 arms), sponsored by Blueprint Medicines. Primary endpoints: Maximum tolerated dose determination of BLU-945 monotherapy and BLU-945 plus osimertinib, Recommended phase 2 dose determination and 2 more. Started Dec 2021; status: completed.
02
Drugs
tigozertinibosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031210431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210431.